argenx Gestion
Gestion contrôle des critères 3/4
Le PDG argenx est Tim Van Hauwermeiren, nommé en Apr2008, a un mandat de 18.08 ans. La rémunération annuelle totale est $ 4.57M, composée du salaire de 18.1% et des bonus 81.9%, y compris les actions et options de la société. détient directement 0.12% des actions de la société, d'une valeur de € 48.16M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.3 ans et 8 ans.
Informations clés
Tim Van Hauwermeiren
Directeur général
US$4.6m
Rémunération totale
| Pourcentage du salaire du PDG | 18.09% |
| Durée du mandat du directeur général | 18.1yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 4.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 8yrs |
Mises à jour récentes de la gestion
Recent updates
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.
ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power
Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential
The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside
Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing
Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks
Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks
Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations
Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm
Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You
Aug 01
We Think argenx (EBR:ARGX) Can Stay On Top Of Its Debt
Jun 30We Take A Look At Whether argenx SE's (EBR:ARGX) CEO May Be Underpaid
May 21
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Dec 31 2025 | US$5m | US$827k | US$1b |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$1b |
| Mar 31 2025 | n/a | n/a | US$1b |
| Dec 31 2024 | US$8m | US$758k | US$833m |
| Sep 30 2024 | n/a | n/a | -US$40m |
| Jun 30 2024 | n/a | n/a | -US$204m |
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$12m | US$656k | -US$295m |
| Sep 30 2023 | n/a | n/a | -US$234m |
| Jun 30 2023 | n/a | n/a | -US$397m |
| Mar 31 2023 | n/a | n/a | -US$511m |
| Dec 31 2022 | US$8m | US$639k | -US$710m |
| Sep 30 2022 | n/a | n/a | -US$909m |
| Jun 30 2022 | n/a | n/a | -US$907m |
| Mar 31 2022 | n/a | n/a | -US$595m |
| Dec 31 2021 | US$7m | US$652k | -US$408m |
| Sep 30 2021 | n/a | n/a | -US$373m |
| Jun 30 2021 | n/a | n/a | -US$319m |
| Mar 31 2021 | n/a | n/a | -US$573m |
| Dec 31 2020 | US$9m | US$641k | -US$608m |
| Sep 30 2020 | n/a | n/a | -US$535m |
| Jun 30 2020 | n/a | n/a | -US$359m |
| Mar 31 2020 | n/a | n/a | -US$275m |
| Dec 31 2019 | US$7m | US$589k | -US$181m |
Rémunération vs marché: La rémunération totale de Tim ($USD 4.57M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Belgian ($USD 2.88M ).
Rémunération et revenus: La rémunération de Tim a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Tim Van Hauwermeiren (53 yo)
Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, EMBA, serves as Independent Non-Executive Director of Lexeo Therapeutics, Inc since July 2024. He had been Independent Director at iTeos Therapeutics,...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 18.1yrs | US$4.57m | 0.12% € 48.2m | |
| Chief Financial Officer | 4.9yrs | US$4.24m | pas de données | |
| Chief Operating Officer | 3.2yrs | US$6.32m | pas de données | |
| Chief Scientific Officer | 3.3yrs | pas de données | pas de données | |
| General Counsel & Corporate Secretary | 4.3yrs | pas de données | pas de données | |
| Vice President of Corporate Development & Strategy | 10yrs | pas de données | pas de données | |
| Global Head of Quality | 6.3yrs | pas de données | pas de données | |
| Chief Medical Officer | 4.1yrs | pas de données | pas de données | |
| Co-Founder & Member of Board Advisors | no data | pas de données | pas de données | |
| Chief Technology Innovation Officer | 4.1yrs | pas de données | pas de données | |
| Global Head of Human Resources | 7.4yrs | pas de données | pas de données | |
| Global Head of Digital Technologies | less than a year | pas de données | pas de données |
Gestion expérimentée: L'équipe de direction de ARGX est considérée comme expérimentée (ancienneté moyenne 4.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 11.8yrs | US$4.57m | 0.12% € 48.2m | |
| Co-Founder & Member of Board Advisors | no data | pas de données | pas de données | |
| Independent Chairman of the Board | 11.8yrs | US$536.90k | 0.0037% € 1.5m | |
| Independent Vice Chairman | 9.1yrs | US$477.40k | 0.0037% € 1.5m | |
| Non-Executive Director | 2yrs | US$484.90k | 0.0016% € 660.5k | |
| Member of Board Advisors | no data | pas de données | pas de données | |
| Independent Non-Executive Director | 8yrs | US$492.40k | 0.0022% € 909.8k | |
| Independent Non-Executive Director | 10.1yrs | US$472.40k | 0.0037% € 1.5m | |
| Member of Board Advisors | no data | US$622.58k | pas de données | |
| Independent Non-Executive Director | 3.3yrs | US$490.84k | 0.0024% € 976.2k | |
| Independent Non-Executive Director | 3.7yrs | US$464.90k | 0.0030% € 1.3m | |
| Independent Non-Executive Director | 3.4yrs | US$475.84k | 0.0021% € 864.1k |
Conseil d'administration expérimenté: Les membres du conseil d'administration de ARGX sont considérés comme expérimentés (ancienneté moyenne 8 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/02 10:30 |
| Cours de l'action en fin de journée | 2026/04/30 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
argenx SE est couverte par 55 analystes. 29 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Baird |
| Colleen Kusy | Baird |
| Joel Beatty | Baird |